Adult human mesenchymal stem cells ( DrugBank: Adult human mesenchymal stem cells )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
85特発性間質性肺炎1
96クローン病4

85. 特発性間質性肺炎


臨床試験数 : 627 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02013700
(ClinicalTrials.gov)
November 13, 20132/12/2013Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs);Biological: matched placeboJoshua M HareThe Lester And Sue Smith Foundation;The Emmes Company, LLCTerminated40 Years90 YearsAll9Phase 1United States

96. クローン病


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01233960
(ClinicalTrials.gov)
November 29, 20102/11/2010Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's DiseaseA Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's DiseaseCrohn's DiseaseDrug: adult human mesenchymal stem cellsMesoblast, Inc.NULLCompleted18 Years70 YearsAll73Phase 3United States;Australia;New Zealand
2NCT00482092
(ClinicalTrials.gov)
September 17, 200730/5/2007Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's DiseaseA Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's DiseaseCrohn's DiseaseDrug: Prochymal®;Drug: PlaceboMesoblast, Inc.NULLCompleted18 Years70 YearsAll330Phase 3United States;Australia;Canada;New Zealand
3NCT00543374
(ClinicalTrials.gov)
September 17, 200711/10/2007Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's DiseaseA Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Durability and Retreatment Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Maintenance and Re-induction of Clinical Benefit and Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's DiseaseCrohn's DiseaseDrug: Placebo;Drug: PROCHYMAL adult human mesenchymal stem cellsMesoblast, Inc.NULLCompleted18 Years70 YearsAll98Phase 3United States;Canada
4NCT00294112
(ClinicalTrials.gov)
March 13, 200617/2/2006Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's DiseaseA Phase II, Open-label, Randomized Study to Evaluate the Safety and Efficacy of PROCHYMAL™ IBD (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects Experiencing Moderate-to-severe Crohn's Disease That is Refractory to Steroids and Immune SuppressantsCrohn's DiseaseDrug: Prochymal™ adult human mesenchymal stem cells;Drug: adult human mesenchymal stem cellsMesoblast, Inc.NULLCompleted18 Years70 YearsAll10Phase 2United States